# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants

> **NCT01964651** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42165279 50 mg
- **DRUG:** JNJ-42165279 100 mg
- **DRUG:** JNJ-42165279 30 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01964651
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01964651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01964651, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01964651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*